|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Denmark
Espicom Business Intelligence Ltd, Sep 2009, Pages: 110
This in-depth pharmaceutical market report is ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Executive Summary
The size of the pharmaceutical market in Denmark is estimated to be US$3.9 billion in 2009, equal to US$711 per capita. The primary care sector constitutes nearly three quarters of the total market size. The market is expected to expand by 8.0% per annum between 2009 and 2014. By 2014, the market is estimated to be worth US$6.4 billion, equal to US$1,134 per capita.
Denmark has a stable political system and a stable economy. However, Denmark is likely to be affected by the global economic downturn, with GDP real growth expected to fall to -3.5% in 2009, according to figures from the Economist Intelligence Unit, and gradually rising to reach a real growth of 2.0% in 2014.
Due to the presence of Novo Nordisk, Denmark is a major global supplier of insulin in retail form. This has resulted in a long-standing balance of trade surplus, which was in excess of US$4.7 billion in 2008. Between 2004 and 2008, imports increased by a CAGR of 11.9% to US$3.2 billion, while exports increased by a CAGR of 10.5% to US$7.9 billion.
Healthcare expenditure has continued its steady growth in the past few years, increasing by 7.1% to reach DKK118.3 billion (US$21.7 billion) in 2007, with private expenditure accounting for around 16% of the total.
Although companies are free to set their own prices, products will only be reimbursed at the level of the lowest generic drug in each class unless it can be shown that there is a distinct therapeutic benefit. This has proved to be an effective way to drive pharmaceutical prices down.
Customers who bought this item also bought
The Medical Device Market: Denmark
The Pharmaceutical Market: Austria
The Pharmaceutical Market: Norway
The Pharmaceutical Market: Sweden
The Pharmaceutical Market: Finland
The Pharmaceutical Market: Israel
The Pharmaceutical Market: Slovakia
The Pharmaceutical Market: Czech Republic
Global Healthcare Information Technology (2009 - 2014)
Pharmaceutical Company Outlook to 2014
The Pharmaceutical Market: Brazil
The Pharmaceutical Market: South Korea
|
|
|
|
